ASTRAZENECA PLC (NYSE: AZN)

Sector: Medical

Current Price : $52.17

52 Week Low
$40.0352 Week High
$52.17

Company

Overview

Research Notes

Company Profile

Competitors

Technicals

Press Releases
SumTotal Named a "Champion" in McLean & Company's Talent Management Suites Vendor Landscape Report
Results from Phase III Studies of Naloxegol for Treatment of Opioid-Induced Constipation Presented at Digestive Disease Week 2013
Assessing Your Asthma is Key to Taking Control
Sub-Group Analysis Shows Investigational Metreleptin Treatment Demonstrated Reductions in HbA1c, Triglycerides and Liver Function Tests in Pediatric Patients with Lipodystrophy During a 12-Month Period
AstraZeneca to Establish Strategic R&D Center in Gaithersburg, Md; Wilmington Remains North America Commercial Headquarters
Factors Moving Markets- Research Report on Actavis, Inc., AstraZeneca PLC, Bristol-Myers Squibb Company, Gilead Sciences Inc. and Novo Nordisk
The Real Story Behind AZN, PPG, RHT and BA
AstraZeneca Encourages Atherosclerosis Education among High Risk Patients during American Heart Month
AstraZeneca Recognized as a Top Company for Female Executives
Free Research Report on Emerson Electric Co., Target Corp., AstraZeneca Plc and Penn National Gaming, Inc.
AstraZeneca HealthCare Foundation: Connections for Cardiovascular HealthSM Accepting Grant Applications
BRILINTA (Ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of STEMI Patients
CRESTOR? US Patent Upheld by Court of Appeals for the Federal Circuit
The Real Story Behind WMB, AZN, GE and AU
AstraZeneca Updates US Label For FASLODEX? (fulvestrant) Injection
Final Overall Survival Analysis of CONFIRM Shows a 4.1 Month Difference in Median Overall Survival When Using FASLODEX? (fulvestrant) Injection 500 mg Compared with 250 mg.1,2
AstraZeneca to Present Key New Data for Hormone Receptor-Positive Metastatic Breast Cancer at the 35th CTRC-AACR Annual San Antonio Breast Cancer Symposium
AstraZeneca Makes Major Commitment to Help Patients with Acute Coronary Syndrome Have BRILINTA (ticagrelor) Available in Their Local Communities
Forxiga(tm) (dapagliflozin), First-In-Class SGLT2 That Works Independently of Insulin, Now Approved in European Union for Treatment of Type 2 Diabetes
AstraZeneca Launches New Digital Resources for ARIMIDEX? (anastrozole) Tablets to Help Educate Patients About ARIMIDEX Direct
New PLATO Analysis Evaluates the Influence of High-Sensitivity Troponin Biomarker Status in NSTE-ACS Patients Managed with Revascularization or Medical Management
AstraZeneca Begins a New Global Study of FASLODEX? (Fulvestrant) 500 mg Injection in Patients With Hormone Receptor-Positive Advanced Breast Cancer
AstraZeneca Begins a New Global Study of FASLODEX? (fulvestrant) Injection in Patients with Hormone Receptor-Positive Advanced Breast Cancer
Where We Are Headed -- New Outlook on Bristol-Myers Squibb Company and AstraZeneca Plc
New PLATO Sub-Analysis Suggests Patients' Age Had No Impact on Study Finding of a Greater Reduction in Thrombotic Cardiovascular Events With BRILINTA (ticagrelor) Compared to Clopidogrel
BRILINTA (ticagrelor) Launches "Complete the Course" ? a Creative Education Program for Patients With ACS, Including "Access My BRILINTA" Support Service Focused on Continuity of Care
AstraZeneca And The Broad Institute Partner To Advance Discovery Of Antibacterial And Antiviral Agents
New Data Suggest Patient Smoking Habits Had No Impact on PLATO Study Findings of a Greater Reduction in Thrombotic Cardiovascular Events with BRILINTA (ticagrelor) Compared to Clopidogrel
New ESC Guidelines Recommend BRILINTA (Ticagrelor) in Acute Coronary Syndromes Patients with ST-Elevation
Pooled Analysis Showed Onglyza? (saxagliptin) Provided Improvements in Key Measures of Blood Sugar Control in Adults with Type 2 Diabetes at High Risk for CV Disease
BRILINTA (ticagrelor) Receives Additional Class I Recommendation in Updated ACCF/AHA Guidelines for the Management of UA/NSTEMI Patients
AstraZeneca and Leading Academic Scientists to Collaborate on Alzheimer's Disease Research
AstraZeneca Acquires Neuroscience Assets From Link Medicine
AstraZeneca And Cellworks Collaborate To Find New Treatment For Tuberculosis
New Data Show Investigational Compound Dapagliflozin Demonstrated Significant Reductions in Blood Sugar Levels When Added to Sitagliptin in Adults with Type 2 Diabetes at 24 Weeks, with Results Maintained Over 48 Weeks
Plan to Speed Up FDA Reviews Recently Approved by Senate
Data Presented at the European Atherosclerosis Society Congress Reinforces the Differentiating Benefits of CRESTOR[TM] in Comparison to Atorvastatin and Simvastatin
SYMBICORT? (budesonide/formoterol fumarate dihydrate) Long-Term Study Shows Similar Safety Profile When Compared to Budesonide Monotherapy in African-American Patients with Asthma
LUNAR Examines Cholesterol-Lowering Effects of CRESTOR? (rosuvastatin calcium) Compared with Atorvastatin in Patients with Acute Coronary Syndrome
Critical Alerts For MasterCard, Celgene, Tempur-Pedic, AstraZeneca, and Sotheby's Released By InvestorsObserver
AstraZeneca and The Medicines Company Announce Global Collaboration in Acute Ischemic Heart Disease
Ardea Biosciences, Inc. (RDEA) Shareholder Alert: Bernstein Liebhard LLP Announces Investigation of Acquisition by AstraZeneca PLC
A Forward Look, the Year Ahead -- Featured Research on Anthera Pharmaceuticals, Inc. and AstraZeneca plc (ADR)
AstraZeneca Launches DUTOPROL(tm) (metoprolol succinate extended release/hydrochlorothiazide) Tablets for High Blood Pressure in U.S.
US District Court Finds SEROQUEL XR Formulation Patent Valid and Infringed
Crestor Delivers Latest LDL-C Targets in High-Risk Patients at Lower Doses than Other Statins
US Court Denies Preliminary Injunction Application against the FDA and Dismisses AstraZeneca's Lawsuit without Prejudice
New Data Suggests BRILINTA? (ticagrelor) Reduced First and Recurrent Cardiovascular and Ischemic Events
New Data Suggests Results of PLATO Genetic Sub-Study Outcomes for BRILINTA? (Ticagrelor) Not Driven by Poor Metabolizers of Clopidogrel
AstraZeneca Announces Increased Coverage of BRILINTA (Ticagrelor) Through Plan Preferred Formulary Status on Medco Health Solutions
AstraZeneca Files Lawsuit against the FDA for Decision Regarding Quetiapine Product Labeling and Exclusivity
FDA Responds to AstraZeneca Citizen Petitions on Quetiapine Product Labeling
European Slowdown Taking Toll on Big Pharma
Delaware to Participate in Real-World Evidence Collaboration with Astrazeneca and HealthCore
BRILINTA? (ticagrelor) Added to American College of Chest Physicians Recommendations on Antithrombotic Therapy and Prevention of Thrombosis
Pharmaceutical Employees Fearful of Losing Jobs as Patent Cliffs Loom
AstraZeneca US Broadens Income Eligibility for Prescription Savings Programs
AstraZeneca Recognized as a Top Company for Female Executives
AstraZeneca Fourth Quarter and Full-Year 2011 Results - Interviews
New Revenues Drivers From Eli Lilly and AstraZeneca Poised to Offset Patent Cliffs
New Data Show Investigational Compound Dapagliflozin When Added to Glimepiride Maintained Reductions in Blood Sugar Levels in Adults with Type 2 Diabetes Over 48 Weeks of Treatment
Despite Trend of Therapeutic Substitution, Survey Data Shows Patients Want Their Physician to Be the Ultimate Decision Maker on Their Rx Medications
KOMBOGLYZE(TM) Receives Marketing Authorisation in the European Union for Adult Patients With Type 2 Diabetes
ONGLYZA? (saxagliptin) Approved for Use in Europe as Combination Therapy With Insulin (With or Without Metformin) in Adults With Type 2 Diabetes
U-M Medical School and MedImmune Join Forces To Accelerate Search for New Therapies
Gingrich think tank brings in $37 million
CAPRELSA(tm) (vandetanib) Receives Positive CHMP Opinion in the European Union for Treating Advanced Medullary Thyroid Cancer
Meta-Analysis of Clinical Data on Cardiovascular Safety Presented for Investigational Compound Dapagliflozin in Adult Patients with Type 2 Diabetes
SATURN Demonstrated Effect of Intensive Statin Treatment on Reducing Atherosclerosis
INSERTING and REPLACING BRILINTA(tm) (ticagrelor) Receives Additional Class I Recommendation in New U.S. Guidelines from ACCF/AHA/SCAI for PCI
BRILINTA(tm) (ticagrelor) Receives Additional Class I Recommendation in New U.S. Guidelines from ACCF/AHA/SCAI for PCI
New CRESTOR? (rosuvastatin calcium) Savings Card Program Provides Instant Savings to Patients
MedImmune Announces Winners of European Cancer Research Abstract Competition
U.S. Food and Drug Administration Extends Action Date for Dapagliflozin by Three Months
On World Arthritis Day, AstraZeneca Encourages Greater Awareness, Education of Osteoarthritis
Maven Semantic: Bone Cancer Research Database
MedImmune In-Licenses Cancer Immunotherapy Tremelimumab from Pfizer
POZEN Announces Engaging Keelin Reeds Partners LLC to Assist With PA32540 Strategic Partner Search
AstraZeneca Enters Into a Settlement Agreement with Handa Pharmaceuticals regarding U.S. SEROQUEL XR? Patent Litigation
ONGLYZA(tm) (saxagliptin) When Added to Insulin in Adults with Type 2 Diabetes Maintained Reductions in Blood Sugar Levels (HbA1c) Over 52 Weeks in Investigational Study Extension
SuperGen, Inc. Changes Name to Astex Pharmaceuticals, Inc., Announces New Stock Ticker Symbol and New Website
New Survey Shows Only One-Third of Americans Know Their Cholesterol Levels
NEXIUM? (esomeprazole magnesium) Launches New Savings Card Offering Instant Discounts for Patients
Research on AstraZeneca plc and Abbott Laboratories - Restructuring Efforts Help but New Drugs Still Key for Big Pharma
BRILINTA(tm) (ticagrelor) Tablets Now Available in U.S. Pharmacies for Patients with Acute Coronary Syndrome
Pozen Patents Upheld in Treximet Patent Litigation
AstraZeneca Announces U.S. Enrollment Opportunities for KODIAC Study to Investigate an Experimental Drug for Constipation from Opioids
FDA Approves New Medicine BRILINTA(TM) (ticagrelor) For Use in the US
FDA Advisory Committee Makes Recommendation on Investigational Compound Dapagliflozin
FDA: Diabetes drug may up cancer risk
Ligand Pharmaceuticals, Inc. Secures $10 Million from Square 1 Bank
AstraZeneca and PTC Therapeutics Announce Strategic Oncology Drug Discovery Collaboration With Potential Extension to Other Therapeutic Areas
Asking the Right Questions May Lead to Earlier Intervention in Pre-Diabetes
Investigational Compound Dapagliflozin with Metformin Extended-Release (XR) as Initial Combination Therapy Significantly Improved Blood Sugar Control in Previously-Untreated Adult Type 2 Diabetes Patients with High Blood Sugar Levels
Investigational Compound Dapagliflozin Added to Metformin Sustained Reductions in Blood Sugar Levels in Adult Patients with Type 2 Diabetes in Two-Year Study
Investigational Compound Dapagliflozin Sustained Glycemic Control and Weight Reduction in Study of Type 2 Diabetes Patients Inadequately Controlled with Metformin
Investigational Study Reported ONGLYZA(TM) (saxagliptin) Added to Insulin Significantly Improved Blood Sugar Levels in Adults with Type 2 Diabetes Compared to Placebo Added to Insulin
DENTSPLY International Announces Agreement to Acquire Astra Tech from AstraZeneca
AstraZeneca Installs 7,300-Panel Solar Energy System on Wilmington Campus
AstraZeneca Sponsors the 2011 National Senior Games

Two Week FREE Trial

iStock Rating

ASTRAZENECA PLC (NYSE: AZN)

Sector: Medical

Company

Community

Analysis

Charts

Analyst

Ratios